Tereza Ševčíková, Ph.D.
Tereza Sevcikova is a researcher in the field of cancer genomics with background in Molecular Biology and Genetics. Currently, Tereza works as a postdoctoral fellow, dedicating her expertise to the genomics of myeloma. In this role, she is involved in project design and plays a role in interpreting results, contributing substantially to the ongoing efforts
Sandra Charvátová, M.D., Ph.D.
Dr. Sandra Charvátová is a pioneering scientist and a clinician specializing in hematologic malignancies and innovative cell-based therapies. With expertise spanning Biophysics, General Medicine, and a Ph.D. in Biology, she’s a driving force in our research group. As the leader of our Transfer Unit, her focus is on transforming laboratory breakthroughs into advanced cell-based therapies
Zuzana Chyra, Ph.D.
Dr. Zuzana Chyra, an accomplished researcher specializing in hematologic malignancies mainly in molecular and cell biology of multiple myeloma and AL amyloidosis. Currently, she is focused on investigating approaches to NK cell-based immunotherapy in her research pursuits. Dr. Chyra’s extensive experience includes position at renowned institution such as the Jerome Lipper Multiple Myeloma Center at
Matouš Hrdinka, Ph.D.
Dr. Matouš Hrdinka stands at the forefront of cancer biology and molecular immunology research, focusing on uncovering the intricate mechanisms of ubiquitin and kinase oncogenic signaling and advancing antibody and cell-based immunotherapies. With over a decade of experience in both academic and pharmaceutical sectors, Dr. Hrdinka has distinguished himself as an accomplished senior scientist and
Jana Kotulová, Ph.D.
Jana Kotulová is an Assistant Professor at the Faculty of Medicine, University of Ostrava, specializing in hematooncology with a solid background in molecular cell biology and immunology. With a profound focus on investigating the intricate phenomena in cancer biology, Jana is dedicated to advancing our understanding of hematological malignancies and exploring novel therapeutic approaches. Her
Assoc. Prof. Michal Šimíček, Ph.D.
Michal Simicek is the scientific director of the Blood Cancer Research Group. He is interested in biochemical, molecular and cellular aspects of haematologic malignancies with a particular focus on the CAR T-cell based immunotherapy. His expertise covers the fields of protein biochemistry, structural, molecular and cell biology. Michal´s team is devoted to resolve fundamental biological